Contact
Header_1077x260px_About_Profil.jpg

New strategies for the treatment of obesity and metabolic dysfunctions

Targeting the incretin/glucagon system with agonists

Figure 1: Schematic representation of the effects of multi-agonists targeting the receptors for GLP-1/Glucagon, GLP-1/GIP and GLP-1/GIP/Glucagon [28]

In Part I of our blog we reported on dual receptor agonists targeting the incretin/glucagon system to treat obesity and type 2 diabetes mellitus with high efficacy. So far, it has been recognized that the concept of combined targeting of gut hormone receptors is also working in humans [1, 2]. In Part II we will focus on the twincretins GIP and GLP-1 [3] to improve glycaemic control and the tri-agonists GLP-1/GIP/Glucagon to treat obesity, type 2 diabetes mellitus and hepatosteatosis [non-alcoholic steatohepatitis (NASH)].

Read More

Topics: Treating Diabetes

Posted by Dr. Ulrike Hövelmann on Nov 13, 2018 5:09:00 PM
dr-ulrike-hövelmann

What news in the treatment of Type 2 diabetes was presented at EASD 2018?

The annual meeting of the European Association for the Study of Diabetes (EASD) took place this year in Berlin, Germany. The present text offers a selection of topics relevant for the field of type 2 diabetes mellitus (T2DM) discussed during that meeting.

Read More

Topics: The Science behind Diabetes, Diabetes Technology, Clinical Trial Methods

Posted by Dr. Jorge Arrubla on Nov 6, 2018 5:09:00 PM
dr-jorge-arrubla

Profil at 18th Annual Diabetes Technology Meeting

Profil will be present at the 18th Annual Diabetes Technology Meeting with two posters and a presentation as invited speaker. The Annual DTM will take place from November 8 to November 10, 2018, in North Bethesda, Maryland. We are looking forward to this exciting event.

Read More

Topics: The Science behind Diabetes, Diabetes Technology, Clinical Trial Methods

Posted by Svenya Meister on Oct 29, 2018 5:15:00 PM
svenya-meister

Artificial Intelligence to Screen for Diabetic Retinopathy; The Times They Are A-Changin‘.

The far majority of clinical trials in diabetes exclude patients with active retinal disease, as interventions that lower glucose rapidly can temporarily worsen retinopathy. This was originally shown in type 1 diabetes [1] but more recently also in type 2 diabetes [2, 3]. Screening for diabetic retinopathy before inclusion in a clinical trial is relatively cumbersome, also because it often involves a separate visit to an ophthalmologist. The use of a fundus camera with offline interpretation by an ophthalmologist has gained widespread use in clinical practice, but not so much in the field of clinical trials.

In this blog I will briefly describe four recent studies on artificial intelligence approaches to automate the interpretation of retinal images. I will conclude with an outlook on how this may facilitate the screening of potential trial participants for diabetic retinopathy. But first a brief introduction to deep learning, the methodology applied in all these papers.

Read More

Topics: Treating Diabetes, The Science behind Diabetes, Diabetes Technology

Posted by Prof. Hans de Vries on Oct 23, 2018 5:18:00 PM
prof-hans-de-vries

New timelines for the EU Portal and implementation of the EU Clinical Trial Regulation

The EU Clinical Trial Regulation No 536/2014 (CTR), which aims to harmonise the assessment and supervision for clinical trials throughout EU Member States, was originally planned to come into application this month (October 2018). As reported earlier, the implementation of the CTR depends on the availability of a functional EU Portal, the single entry point for submitting clinical trial information in the EU, and database.

Read More

Topics: Clinical Trials in Diabetes

Posted by Dr. Grit Andersen on Oct 17, 2018 5:12:00 PM
dr-grit-andersen

"Profil World" - The clinical diabetes research newsletter - October 2018

Dear all,

Greetings from Germany! I am happy to share with you the newest edition of "Profil World" - our newsletter filled with information about clinical research in diabetes and obesity.

Read More

Topics: About Profil

Posted by Dr. Lars Bochmann on Oct 11, 2018 5:21:00 PM
dr-lars-bochmann

54th EASD Annual Meeting – Profil’s contributions to the scientific sessions

Berlin, Germany, 1-5 October 2018

Last week our team joined an exciting and busy 54th EASD Annual Meeting in Berlin. We would like to give you a brief overview about those orals and posters presenting results from clinical trials Profil had been involved in.

Read More

Topics: Treating Diabetes, Diabetes Technology, The Science behind Diabetes

Posted by Dr. Sabine Arnolds on Oct 10, 2018 4:15:43 PM
dr-sabine-arnolds

Profil explores opportunities for artificial pancreas in type 2 diabetes

Highlighting the role of open and trans-sectoral collaboration in the advancement of artificial pancreas solutions

Profil has recently published a peer-reviewed article on the topic of “Artificial Pancreas Systems for People With Type 2 Diabetes: Conception and Design of the European CLOSE Project ” in the Journal of Diabetes Science and Technology. Profil is the organisation coordinating CLOSE. The article is authored by CLOSE industry and academic partners, representatives of the EIT Health public-private partnership management boards, and key opinion leaders in the field.

Read More

Topics: Treating Diabetes, Diabetes Technology, The Science behind Diabetes

Posted by Prof. Dr. Freimut Schliess on Oct 2, 2018 5:18:00 PM
prof-dr-freimut-schliess

Work stress is the new smoking

According to the WHO, about 31% of all deaths worldwide (17.7 million deaths per year) [1] are attributable to cardiovascular disease (CVD), making CVDs the number 1 cause of death globally. Known risk factors for the development of CVD, among others, are smoking, high blood pressure or the lack of physical activity. Especially the latter has been discussed in the recent years and it became known that long hours of sitting [2] may increase your risk of CVD and diabetes (and may apparently even increase mortality, in the case of binge watching [3]). While numerous risk factors for CVD are known and several recommendations and guidelines on how to handle them exist, the prognostic role of what may possibly be one of the most common and important factors on cardiovascular health nowadays has not yet been formally assessed: stress at work.

Read More

Topics: Treating Diabetes, Clinical Trials in Diabetes

Posted by Dr. Theresa Herbrand on Sep 25, 2018 5:12:00 PM
dr-theresa-herbrand

Profil at EASD Annual Meeting 2018

About EASD Annual Meeting

Profil will be present at EASD Annual Meeting with numerous posters as well as some presentations. Of course we look forward to this exciting event very much. 

We are proud that Profil will be a sponsor of Solvable Problems in Diabetes at EASD Annual Meeting 2018 in Berlin. The event will take place on Thursday, October 4, 2018, from 7:00-9:00 pm during the 2018 annual meeting for the European Association of the Study of Diabetes (EASD). Learn more about the event here

To meet Profil at the EASD Annual Meeting please fill out the request form at our website.

Read More

Topics: About Profil

Posted by Dr. Lars Bochmann on Sep 14, 2018 12:21:35 PM
dr-lars-bochmann

Subscribe to our monthly blog updates

Neuer Call-to-Action 

Subscribe to Email Updates

Our most popular Posts